How were Viela Bio's earnings last quarter?

Viela Bio, Inc. (NASDAQ:VIE) posted its quarterly earnings data on Sunday, February, 28th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.10. The company had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.10 million.

When did Viela Bio IPO?

Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

NASDAQ:VIE

Viela Bio (VIE) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free VIE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $53.01
▼
$53.01
50-Day Range: $52.92
▼
$53.20
52-Week Range: $25.02
▼
$65.00

Volume: N/A
Average Volume: 1.07 million shs
Market Capitalization: $2.91 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Viela Bio alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Viela Bio Stock (NASDAQ:VIE)

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjÃ¶gren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

VIE Stock News Headlines

April 16, 2024 | finance.yahoo.com

FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight

January 29, 2024 | benzinga.com

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 27, 2024 | bizjournals.com

ArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024

January 9, 2024 | seekingalpha.com

ArriVent Biopharma Seeks $100 Million IPO For Lung Cancer Drug

January 5, 2024 | marketwatch.com

ArriVent BioPharma Files For IPO

December 6, 2023 | finance.yahoo.com

Myasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%

November 17, 2023 | benzinga.com

Global CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key Players

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 9, 2023 | uk.finance.yahoo.com

Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies

November 3, 2023 | finance.yahoo.com

Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy

October 25, 2023 | bizjournals.com

Amgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for now

October 23, 2023 | finanznachrichten.de

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

September 20, 2023 | usatoday.com

Inside 'Elon Musk': Wild details from revealing Walter Isaacson biography

July 26, 2023 | nypost.com

I’m an AI influencer: Followers crave my sexy snaps — but I don’t exist

May 8, 2023 | marketwatch.com

2023 Cutaneous Lupus Erythematosus (CLE) Treatment Market: Latest Technology Innovations and Comprehensive Growth Insights by 2031

May 5, 2023 | marketwatch.com

Cutaneous Lupus Erythematosus (CLE) Treatment Market: Opportunities for Industry Expansion in 2030

May 5, 2023 | marketwatch.com

8-K: Horizon Therapeutics Public Ltd Co

March 27, 2023 | bizjournals.com

ArriVent Biopharma raises $155M in one of largest local funding rounds of 2023

March 9, 2023 | marketwatch.com

Cutaneous Lupus Erythematosus (CLE) Treatment Market Application, Product, Sales and Forecast 2023-2028

February 10, 2023 | marketwatch.com

Exploring the Challenges and Opportunities in the Cutaneous Lupus Erythematosus (CLE) Treatment Market (2023-2028)

January 20, 2023 | marketwatch.com

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market is Set to Grow in forecast period 2029

December 13, 2022 | bizjournals.com

With Horizon acquisition, Amgen would enter Montgomery County for the first time. Here’s what we know.

December 1, 2022 | bizjournals.com

Horizon Therapeutics spells out vision for Rockville R&D hub

November 16, 2022 | bizjournals.com

Life sciences firm MilliporeSigma doubling down on MoCo with $286M investment

November 15, 2022 | seekingalpha.com

SBI Holdings, Inc. (SBHGF) Q2 2023 Earnings Call Transcript

November 2, 2022 | msn.com

Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday

See More Headlines

Receive VIE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2021
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VIE
CUSIP: N/A
CIK: N/A
Web: www.vielabio.com
Phone: 240 558 0038
Fax: N/A
Employees: 166
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-86,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.97%
Return on Assets: -31.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.51
Quick Ratio: 19.49

Sales & Book Value

Annual Sales: $50 million
Price / Sales: 58.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.14 per share
Price / Book: 7.42

Miscellaneous

Outstanding Shares: 54,950,000
Free Float: N/A
Market Cap: $2.91 billion
Optionable: Not Optionable
Beta: 0.43

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Zhengbin Yao (Age 55)
Chairman, Pres & CEO
Comp: $846.75k
Mr. Mitchell Chan (Age 40)
Chief Financial Officer
Comp: $420.34k
Dr. JÃ¶rn Drappa M.D. (Age 56)
Ph.D., Chief Medical Officer and Head of R&D
Comp: $637.39k
Mr. James Paul Kastenmayer J.D. (Age 49)
Ph.D., Gen. Counsel & Company Sec.
Ms. Kate Surdez
Sr. VP & Head of HR
Ms. Rachel Ettinger
Sr. Director & Head of Research
Mr. Bill Rees
Sr. Director & Head of Translational Science
Mr. Ted Phillips
VP & Head of Clinical Operations
Mr. Dewei She
Sr. Director and Head of Biostatistics, Data Management, & Programming
Mr. Lee Levin
Sr. Director & Head of Quality

Key Competitors

View All Competitors

VIE Stock Analysis - Frequently Asked Questions

How were Viela Bio's earnings last quarter?: Viela Bio, Inc. (NASDAQ:VIE) posted its quarterly earnings data on Sunday, February, 28th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.10. The company had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.10 million.
When did Viela Bio IPO?: Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

This page (NASDAQ:VIE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Viela Bio (VIE) Stock Price, News & Analysis

About Viela Bio Stock (NASDAQ:VIE)

VIE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VIE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info